UPF 648

Key Product Details

Product Description

UPF 648 is a potent kynurenine 3-monooxygenase (kynurenine 3-hydroxylase; KMO) inhibitor (IC₅₀ = 20 nM). Increases kynurenic acid levels, and decreases 3-HK and QUIN levels in cerebrum and liver of neonatal rodents. Neuroprotective in a Drosophila model of Huntington's disease.

Product Specifications for UPF 648

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for UPF 648

The following data is based on the product molecular weight 259.09.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	3.86 mL	19.30 mL	38.60 mL
5 mM	0.77 mL	3.86 mL	7.72 mL
10 mM	0.39 mL	1.93 mL	3.86 mL
50 mM	0.08 mL	0.39 mL	0.77 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 3 publications citing the usage of this product.

• Campesan The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease. Curr.Biol. 2011 PMID: 21636279
• Amaral Structural basis of kynurenine 3-monooxygenase inhibition. Nature 2013 PMID: 23575632
• Amori On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo. J.Neurochem. 2009 PMID: 19226371
• Ceresoli-Borroni Perinatal kynurenine 3-hydroxylase inhibition in rodents: pathophysiological implications. J.Neurosci.Res. 2007 PMID: 17279543

Product Documents for UPF 648